Inherited Retinal Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Novartis, Spark Therapeutics, Endogena Therapeutics, Aldeyra Therapeutics, GenSight Biologics

Inherited Retinal Disease therapies, such as LUXTURNA, GS030, EA-2353, ADX-2191, and others, are expected to boost the Inherited Retinal Disease Market in the upcoming years.

DelveInsight has launched a new report on "Inherited Retinal Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Inherited Retinal Disease, historical and forecasted epidemiology as well as the Inherited Retinal Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Inherited Retinal Disease market report @ https://www.delveinsight.com/report-store/inherited-retinal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Inherited Retinal Disease Market Report:

The Inherited Retinal Disease (IRD) market is expected to experience steady growth at a consistent compound annual growth rate (CAGR) from 2024 to 2034. This increase in market revenue is mainly driven by a rise in genetic mutations and the growing number of diagnosed cases. Although there is currently no cure for IRDs, factors such as advances in genetics and genomics, collaborative research, clinical trials, technological innovations, and the expanding field of precision medicine are fueling ongoing research, drug development, and treatment options.
The present IRD market is marked by limited competition, with only a few companies like Novartis and Spark Therapeutics having approved treatments for the condition. In emerging markets, growth is expected to be slow due to the limited availability of treatment options. Most approved therapies address complications of IRD rather than offering a cure.
Looking ahead, companies such as Endogena Therapeutics, Aldeyra Therapeutics, and GenSight Biologics are advancing their therapies through mid to late-stage development. With anticipated approvals during the forecast period (2024-2034), the IRD therapeutic market is projected to grow significantly at a strong CAGR.
The analysis revealed that choroideremia has an estimated prevalence of about 1 in 50,000 individuals of European descent.
In Japan, retinitis pigmentosa (RP) affects approximately 1 in every 4,000 to 8,000 people. The epidemiology of inherited retinal diseases (IRDs) is anticipated to evolve over the forecast period from 2020 to 2034.
In March 2025, the FDA approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals as the first and only treatment for Macular Telangiectasia type 2 (MacTel). This approval highlights the FDA's commitment to addressing rare retinal diseases through innovative therapies.
Key Inherited Retinal Disease companies such as Novartis, Spark Therapeutics, Endogena Therapeutics, Aldeyra Therapeutics, GenSight Biologics, and others are evaluating new drugs for Inherited Retinal Disease to improve the treatment landscape.
Promising Inherited Retinal Disease therapies include LUXTURNA, GS030, EA-2353, ADX-2191, and others.

Inherited Retinal Disease Overview

Inherited retinal diseases (IRDs) are a diverse group of disorders, both clinically and genetically, characterized by the degeneration or malfunction of photoreceptor cells in the retina. These conditions often lead to significant and progressive vision loss, with symptoms appearing anywhere from birth to late adulthood.

IRDs result from mutations or errors in one or more genes, causing retinal cells to function improperly and gradually leading to vision impairment. To date, approximately 250 genes have been identified as causes of IRDs, though many more remain undiscovered.

Common symptoms include difficulty seeing in low-light or dark environments, loss of peripheral (side) vision that may cause bumping into objects or people, sensitivity to glare, and trouble coping with bright light, among others.

Several types of IRDs have been recognized, with the most prevalent being Retinitis Pigmentosa (RP), Choroideremia, Stargardt Disease, Cone-Rod Dystrophy, and Leber Congenital Amaurosis.

Inherited Retinal Disease Market Outlook

The primary treatment goals for inherited retinal diseases (IRD) are to relieve symptoms, improve patients' quality of life, and potentially slow the disease's progression. Although there is currently no cure, supportive care, complication management, and ongoing research efforts focus on enhancing the overall well-being of those affected.

Treatment options vary depending on the specific condition and may include prescription glasses to improve vision, tints and filters to reduce light sensitivity, or surgical interventions to repair the retina, especially for advanced cases such as X-linked retinoschisis or complications related to severe myopia.

In December 2017, the U.S. Food and Drug Administration (FDA) approved LUXTURNA (voretigene neparvovec-rzyl), a gene therapy for children and adults with an inherited form of vision loss that can lead to blindness. This marked the first FDA-approved gene therapy directly targeting a disease caused by mutations in a specific gene.

With continued research and dedication, there is hope for more effective treatments and ultimately a cure for IRDs. According to DelveInsight, the IRD market in the seven major markets (7MM) is expected to undergo significant changes during the period from 2020 to 2034.

Discover how the Inherited Retinal Disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/inherited-retinal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Inherited Retinal Disease Marketed Drugs
LUXTURNA: Spark Therapeutics/Novartis

Inherited Retinal Disease Emerging Drugs
GS030: GenSight Biologics
EA-2353: Endogena Therapeutics
ADX-2191: Aldeyra Therapeutics

Scope of the Inherited Retinal Disease Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Inherited Retinal Disease Companies: Novartis, Spark Therapeutics, Endogena Therapeutics, Aldeyra Therapeutics, GenSight Biologics, and others
Inherited Retinal Disease Therapeutic Assessment: Inherited Retinal Disease current marketed and Inherited Retinal Disease emerging therapies
Inherited Retinal Disease Market Dynamics: Inherited Retinal Disease market drivers and Inherited Retinal Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Inherited Retinal Disease Unmet Needs, KOL's views, Analyst's views, Inherited Retinal Disease Market Access and Reimbursement

To know what's more in our Inherited Retinal Disease report, visit https://www.delveinsight.com/report-store/inherited-retinal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Inherited Retinal Disease Market Report:
Inherited Retinal Disease market report covers a descriptive overview and comprehensive insight of the Inherited Retinal Disease Epidemiology and Inherited Retinal Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Inherited Retinal Disease market report provides insights into the current and emerging therapies.
The Inherited Retinal Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Inherited Retinal Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Inherited Retinal Disease market.

Got queries? Click here to know more about the Inherited Retinal Disease market Landscape https://www.delveinsight.com/sample-request/inherited-retinal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Inherited Retinal Disease Patient Share (%) Overview at a Glance
5. Inherited Retinal Disease Market Overview at a Glance
6. Inherited Retinal Disease Disease Background and Overview
7. Inherited Retinal Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Inherited Retinal Disease
9. Inherited Retinal Disease Current Treatment and Medical Practices
10. Unmet Needs
11. Inherited Retinal Disease Emerging Therapies
12. Inherited Retinal Disease Market Outlook
13. Country-Wise Inherited Retinal Disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Inherited Retinal Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Inherited Retinal Disease Market Outlook 2034 https://www.delveinsight.com/report-store/inherited-retinal-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Inherited Retinal Disease Pipeline Insights, DelveInsight

"Inherited Retinal Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Inherited Retinal Disease market. A detailed picture of the Inherited Retinal Disease pipeline landscape is provided, which includes the disease overview and Inherited Retinal Disease treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.